Somatic-vegetative Symptoms Evolution in Postmenopausal Women Treated with Phytoestrogens and Hormone Replacement Therapy
AbstractBackground: The purpose of this study was to compare the effects of the phytoestrogens in relieving and/or suppressing the specific somatic-vegetative symptoms of menopause with those of the hormone therapy, administered in small doses.Methods: The study was conducted in the County Clinical Emergency Hospital Oradea - Obstetric-Gynecological Ambulatory, and in private obstetrics-gynecology cabinets from Bihor County (NW Romania), from November 2011 to January 2014. Overall, 325 patients clinically diagnosed with specific postmenopausal symptomatology and not previously treated with phytoestrogens or hormone replacement therapy (HRT), were divided into 3 groups. Symptom assessment was performed with a standardized questionnaire named Menopause Rating Scale (MRS) in three phases: beginning of the treatment, after six months, and after one year. The administered doses for three different groups were as follows: 1 mg estradiol and 0.5 mg norethisterone acetate (NETA) p.o. daily (i.e. for the HRT group); 40 mg of isoflavones p.o. daily - i.e. 2 capsules of 40% standardized extract containing 20 mg of pure isoflavones: Genistein, Daidzein, and Glycitein (i.e. for the group with phytoestrogens); and no trreatment for the control group.Results: The evolution of the somatic-vegetative symptoms was better in both groups treated either with phytoestrogens or HRT (P<0.001) as opposed to the higher percentage of patients with stationary symptoms in the control group (i.e. 37.74% for control group, 16.13% for the group treated with phytoestrogens, respectively 18.95% for the group treated with HRT).Conclusion: Twelve months treatment study is a favorable evidence for the use of soy derived phytoestrogens in the treatment of somatic-vegetative symptoms at postmenopausal women.
Abeer A Al-Eassa, Abeer M Al-Fadel, Maryam A Al-Ajmi, et al (2012). Knowledge and attitude of primary care doctors towards management of postmenopausal symptoms. Alexandria Med J, 48(2):167–73.
Luoto R (2009). Hot flushes and quality of life during menopause. BMC Womens Health, 9:13.
Polo-Kantola P, Saaresranta T, Polo O (2001). Aetiology and treatment of sleep disturbancies during perimenopause and postmenopause. CNS Drugs, 15(6):445-52.
Wulf HU (2005). Psychosocial and socioeco-nomic burden of vasomotor symptoms in menopause: A comprehensive review. Health Qual Life Outcomes, 3:47.
Ţiţ DM (2014). Comparative study on the effects of hormone replacement therapy (HRT) and phytoestrogens in the prevention of postmenopausal osteoporosis [PhD Thesis]. University of Oradea, Oradea.
Palacios S (2008). Advances in hormone re-placement therapy: making the menopause manageable. BMC Womens Health, 8:22.
Bumbu A, Paşca B, Ţiţ D M, Bungău S, Bumbu G (2016). The effects of soy isoflavones and hormonal replacing therapy on the incidence and evolution of postmenopausal female urinary incontinence. Farmacia, 64(3): 419-22.
Hsia J, Simon JA, Lin F et al (2000). Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation, 102(18):2228-32.
Rossouw JE, Anderson GL, Prentice RL et al (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women, principle results from the Women's Health Initiative randomized controlled trial. JAMA, 288(3):321-33.
Crandall C (2003). Low dose estrogen therapy for menopausal women: a review of efficacy and safety. J Womens Health (Larchmt), 12 (8):723-47.
Stevenson JC, Panay N, Pexman-Fieth C (2013). Oral estradiol and dydrogesterone combination therapy in postmenopausal women: Review of efficacy and safety. Maturitas, 76(1):10-21.
Bungău S, Țiț DM, Fodor K, Purza L (2015). The Treatment with Hormone Replacement Therapy and Phytoestrogens and the Evolution of Urogenital Symptoms in Postmenopausal Women. EC Pharm Sci, 1(3): 126-32.
Grodstein F, Manson JE, Stampfer MJ (2006). Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt), 15(1):35-44.
Bolaños R, Del Castillo A, Francia J (2010). Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause, 17(3): 660-6.
Kurzer MS (2008). Soy consumption for reduction of menopausal symptoms. Inflammopharmacology, 16(5): 227-29.
Țiț DM, Lazăr L, Bungău S, Pallag A, Bei D (2013). The evaluation of the effectiveness of phytoestrogens in improving, reduction or suppression of the climacteric symptomatology. Studia Universitatis Vasile Goldiş Arad, Seria Ştiinţele Vieţii, 23(4): 585-89.